Trait Name |
Trait Full Name |
Panel |
Author |
Year |
Cases* |
Controls |
TAG Set Threshold |
CSEA p (chi2) |
Aggression | Aggression | MTC | Pappa | 2015 | NA | 15668 | 5.00e-2 | 4.82e-2 |
BMI Childhood | BMI Childhood | MTC | Felix | 2015 | NA | 34744 | 1.00e-3 | 3.01e-2 |
BMI Childhood | BMI Childhood | MTC | Felix | 2015 | NA | 34744 | 1.00e-4 | 2.51e-2 |
Clozapine Induced Agranulocytosis | Clozapine Induced Agranulocytosis | ETC | Goldstein | 2014 | 161 | 1196 | 5.00e-2 | 3.74e-2 |
Cross Disorder Brain | Cross Disorder Brain | MTC | PGC | 2013 | 33332 | 27888 | 1.00e-4 | 3.15e-2 |
Gout | Gout | MTC | Kottgen | 2013 | 2115 | 67259 | 5.00e-2 | 2.24e-2 |
Hemoglobin A1c | Hemoglobin A1c | ETC | Soranzo | 2010 | NA | 46368 | 5.00e-2 | 2.59e-2 |
Serum Urate | Serum Urate | MTC | Kottgen | 2013 | NA | 110347 | 1.00e-2 | 6.19e-3 |
Tetralogy Of Fallot | Tetralogy Of Fallot | MTC | Cordell | 2013 | 835 | 5159 | 5.00e-2 | 3.67e-2 |
Albuminuria | Urinary Albumin to Creatinine Ratio | MTC | Boger | 2011 | NA | 31580 | 1.00e-2 | 1.85e-2 |
Albuminuria | Urinary Albumin to Creatinine Ratio | MTC | Teumer | 2016 | NA | 54450 | 5.00e-2 | 5.05e-3 |
Albuminuria | Urinary Albumin to Creatinine Ratio | MTC | Teumer | 2016 | NA | 54450 | 1.00e-2 | 3.50e-2 |
Albuminuria | Urinary Albumin to Creatinine Ratio In Diabetics | MTC | Teumer | 2016 | NA | 5825 | 5.00e-2 | 4.63e-5 |
Albuminuria | Urinary Albumin to Creatinine Ratio In Diabetics | MTC | Teumer | 2016 | NA | 5825 | 1.00e-2 | 6.69e-4 |
Albuminuria | Urinary Albumin to Creatinine Ratio In Nondiabetics | MTC | Teumer | 2016 | NA | 46051 | 5.00e-2 | 1.52e-4 |
Alcohol Consumption | Alcohol Consumption All Dichotomous | MTC | Schumann | 2016 | NA | 74711 | 5.00e-2 | 2.24e-2 |
Alcohol Consumption | Alcohol Consumption Men Continuous | MTC | Schumann | 2016 | NA | 27560 | 5.00e-2 | 3.10e-2 |
Alcohol Consumption | Alcohol Consumption Men Dichotomous | MTC | Schumann | 2016 | NA | 26991 | 1.00e-2 | 3.81e-2 |
Alzheimers Protein Levels | Amyloid Beta 1 42 | MTC | Ramirez | 2014 | NA | 363 | 5.00e-2 | 3.69e-2 |
Alzheimers Protein Levels | Amyloid Beta 1 42 | MTC | Ramirez | 2014 | NA | 363 | 1.00e-2 | 2.21e-2 |
Anthropometric Extremes | Obesity Class 2 | MTC | Berndt | 2013 | 9889 | 65840 | 1.00e-3 | 1.65e-2 |
Anthropometric Extremes | Obesity Class 2 | MTC | Berndt | 2013 | 9889 | 65840 | 1.00e-4 | 3.58e-2 |
Anthropometrics Sex Stratified | Waist Hip Ratio Adjusted For BMI Women | MTC | Randall | 2013 | NA | 42969 | 1.00e-4 | 1.79e-2 |
Anthropometrics Sex Stratified | Waist Hip Ratio Women | MTC | Randall | 2013 | NA | 42969 | 1.00e-3 | 2.96e-2 |
Autism | Autism Europeans | ETC | Psychiatric-Genomics-Consortium | 2017 | 6197 | 7377 | 5.00e-2 | 3.53e-2 |
Blood Cells | Neutrophil Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 1.29e-2 |
Blood Cells | White Blood Cell Counts | MTC | Ferreira | 2009 | NA | 6015 | 5.00e-2 | 3.88e-2 |
BMI Physical Activity Interaction | BMI Inactive European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-3 | 2.51e-2 |
BMI Physical Activity Interaction | BMI Inactive European Men | MTC | GIANT | 2017 | NA | 104666 | 5.00e-2 | 4.31e-2 |
BMI Physical Activity Interaction | Waist Circumference Adjusted For BMI Inactive European | MTC | GIANT | 2017 | NA | 234069 | 1.00e-2 | 1.69e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European | MTC | GIANT | 2017 | NA | 234069 | 5.00e-2 | 3.49e-2 |
BMI Physical Activity Interaction | Waist Hip Ratio Adjusted For BMI Active European Men | MTC | GIANT | 2017 | NA | 104666 | 1.00e-2 | 2.38e-2 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-2 | 2.47e-2 |
BMI Smoking Adjusted | Waist Circumference Adjusted BMI Adjusted Smoking Women European | MTC | GIANT | 2017 | NA | 132115 | 1.00e-3 | 2.73e-2 |
Bone Mineral Density | Forearm Bone Mineral Density | ETC | Zheng | 2015 | NA | 6627 | 5.00e-2 | 1.96e-2 |
Diarrhoeal Disease | Diarrhea Doctor Diagnosed Age 1 | MTC | Bustamante | 2016 | 1339 | 5064 | 1.00e-3 | 2.98e-2 |
Ectopic Fat Traits | Pericardial Adipose Tissue Volume Adjusted For Height Weight All | MTC | Chu | 2017 | NA | 7324 | 5.00e-2 | 6.64e-3 |
Ectopic Fat Traits | Visceral Adipose Tissue Attenutation Men | MTC | Chu | 2017 | NA | 5749 | 5.00e-2 | 3.37e-3 |
Ectopic Fat Traits | Visceral Adipose Tissue Attenutation Men | MTC | Chu | 2017 | NA | 5749 | 1.00e-2 | 2.62e-3 |
Ectopic Fat Traits | Visceral Adipose Tissue Volume Men | MTC | Chu | 2017 | NA | 7432 | 1.00e-2 | 4.54e-2 |
Estimated Glomerular Filtration Rate | Cystatin C | MTC | Pattaro | 2016 | NA | 32834 | 1.00e-4 | 1.26e-3 |
Facial Shape | Mod23 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.61e-2 |
Facial Shape | Mod24 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 4.91e-2 |
Facial Shape | Mod25 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.23e-2 |
Facial Shape | Mod35 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 2.05e-2 |
Facial Shape | Mod40 | MTC | Claes | 2018 | NA | 2329 | 1.00e-2 | 1.41e-2 |
Facial Shape | Mod42 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.04e-2 |
Facial Shape | Mod43 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 3.67e-2 |
Facial Shape | Mod47 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 9.93e-3 |
Facial Shape | Mod5 | MTC | Claes | 2018 | NA | 2329 | 1.00e-3 | 4.10e-2 |
Facial Shape | Mod58 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 2.86e-2 |
Facial Shape | Mod60 | MTC | Claes | 2018 | NA | 2329 | 5.00e-2 | 5.02e-3 |
Forced Expiratory Volume | Forced Vital Capacity | MTC | Soler-Artigas | 2015 | NA | 38199 | 5.00e-2 | 2.83e-2 |
Glucose Stimulated Insulin Secretion | AUC Insulin | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-2 | 8.27e-3 |
Glucose Stimulated Insulin Secretion | AUC Insulin | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-3 | 5.11e-3 |
Glucose Stimulated Insulin Secretion | AUC Insulin Over AUC Glucose | MTC | Prokopenko | 2014 | NA | 10837 | 1.00e-3 | 2.98e-2 |
Insulin Secretion | Peak Insulin Response | MTC | Wood | 2017 | NA | 2159 | 1.00e-2 | 4.22e-2 |
Intracerebral Hemorrhage | Nonlobar ICH | MTC | Woo | 2014 | 881 | 1481 | 5.00e-2 | 3.80e-2 |
Kidney Function | CKDi25 | MTC | Gorski | 2015 | NA | 45530 | 1.00e-2 | 1.63e-2 |
Kidney Function | CKDi25 | MTC | Gorski | 2015 | NA | 45530 | 1.00e-3 | 3.59e-2 |
Kidney Function | eGFR Decline With Chronic Kidney Disease | MTC | Gorski | 2015 | NA | 45530 | 5.00e-2 | 4.97e-2 |
Kidney Function | Serum Cystatine | MTC | Gorski | 2017 | NA | 45530 | 5.00e-2 | 3.80e-2 |
Kidney Function | Serum Cystatine | MTC | Gorski | 2017 | NA | 45530 | 1.00e-4 | 2.30e-2 |
Kidney Function | Serum Cystatine | MTC | Gorski | 2017 | NA | 45530 | 1.00e-5 | 1.59e-2 |
Kidney Function | Serum Cystatin | MTC | Kottgen | 2010 | NA | 67093 | 1.00e-2 | 1.26e-2 |
Kidney Function | Serum Cystatin | MTC | Kottgen | 2010 | NA | 67093 | 1.00e-3 | 2.42e-3 |
New Onset Diabetes | New Onset Diabetes After Drugs, European American | MTC | Chang | 2018 | 138 | 414 | 5.00e-2 | 2.21e-3 |
New Onset Diabetes | New Onset Diabetes After Drugs, European American | MTC | Chang | 2018 | 138 | 414 | 1.00e-2 | 6.14e-3 |
Personality Big5 | Agreeableness | MTC | De-Moor | 2012 | NA | 17375 | 5.00e-2 | 4.09e-2 |
Stroke (ischemic) | Large Artery Stroke | MTC | Traylor | 2017 | 2167 | 62004 | 5.00e-2 | 1.30e-2 |
Statin Efficacy | Delta LDL | MTC | Barber | 2010 | NA | 3928 | 1.00e-2 | 4.96e-2 |
Facial attractiveness | Facial attractiveness, female raters | ETC | Hu | 2019 | NA | 3928 | 1.00e-2 | 3.92e-2 |
BMI | Normal body mass index vs thin control, adult vs thin adult | ETC | McKay | 2019 | 6460 | 1471 | 5.00e-2 | 2.82e-2 |
Postburn scar pliability | Postburn scar pliability | ETC | Wallace | 2018 | NA | 665 | 1.00e-3 | 2.22e-2 |
Erectile dysfunction | Erectile dysfunction | ETC | Bovijn | 2018 | 6175 | 217630 | 1.00e-2 | 2.86e-2 |
IHPS | Infantile hypertrophic pyloric stenosis | ETC | Fadista | 2018 | NA | 4438 | 5.00e-2 | 1.36e-2 |
IHPS | Infantile hypertrophic pyloric stenosis | ETC | Fadista | 2018 | NA | 4438 | 1.00e-2 | 7.32e-3 |
IHPS | Infantile hypertrophic pyloric stenosis | ETC | Fadista | 2018 | NA | 4438 | 1.00e-3 | 1.71e-3 |
Medication use | Medication use (antihypertensives) | ETC | Wu Y | 2019 | 6,431 | 145,949 | 5.00e-2 | 1.81e-2 |
Medication use | Medication use (antihypertensives) | ETC | Wu Y | 2019 | 6,431 | 145,949 | 1.00e-2 | 1.46e-2 |
Medication use | Medication use (glucocorticoids) | ETC | Wu Y | 2019 | 17,352 | 188,348 | 1.00e-2 | 1.13e-2 |
Medication use | Medication use (antiglaucoma preparations and miotics) | ETC | Wu Y | 2019 | 5,215 | 95,653 | 1.00e-3 | 4.09e-2 |
Medication use | Medication use (antiglaucoma preparations and miotics) | ETC | Wu Y | 2019 | 5,215 | 95,653 | 1.00e-4 | 7.23e-3 |
Medication use | Medication use (antiglaucoma preparations and miotics) | ETC | Wu Y | 2019 | 5,215 | 95,653 | 1.00e-5 | 5.11e-3 |
Blood urea nitrogen levels | Blood urea nitrogen levels | ETC | Wuttke M | 2019 | NA | 243,029 | 5.00e-2 | 2.85e-3 |
Blood urea nitrogen levels | Blood urea nitrogen levels | ETC | Wuttke M | 2019 | NA | 243,029 | 1.00e-2 | 5.75e-3 |
Blood urea nitrogen levels | Blood urea nitrogen levels | ETC | Wuttke M | 2019 | NA | 243,029 | 1.00e-3 | 9.45e-3 |
Blood urea nitrogen levels | Blood urea nitrogen levels | ETC | Wuttke M | 2019 | NA | 243,029 | 1.00e-4 | 1.43e-3 |
Blood urea nitrogen levels | Blood urea nitrogen levels | ETC | Wuttke M | 2019 | NA | 243,029 | 1.00e-5 | 1.24e-2 |
Diverticular disease | Diverticular disease | ETC | Schafmayer C | 2019 | 31,964 | 419,135 | 1.00e-4 | 1.08e-2 |
Periodontal disease | Periodontal disease related phenotype (PCT6) | ETC | Offenbacher S | 2016 | NA | 975 | 5.00e-2 | 5.65e-3 |
Periodontal disease | Periodontal disease related phenotype (PCT6) | ETC | Offenbacher S | 2016 | NA | 975 | 1.00e-2 | 2.37e-3 |
Longevity | Longevity (age >99th survival percentile) | ETC | Deelen J | 2019 | 3,484 | 25,483 | 1.00e-3 | 4.64e-2 |
Frontal lobe volume | Frontal lobe volume | ETC | van der Lee SJ | 2019 | NA | 15,269 | 5.00e-2 | 2.93e-2 |
Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Teumer A | 2019 | NA | 547,361 | 5.00e-2 | 3.53e-2 |
Albumin to creatinine ratio | Urinary albumin-to-creatinine ratio | ETC | Teumer A | 2019 | NA | 547,361 | 1.00e-2 | 2.02e-2 |
Urate | Urate levels | ETC | Tin A | 2019 | NA | 288,649 | 1.00e-2 | 1.77e-2 |
Uterine fibroids and heavy menstrual bleeding | Uterine fibroids and heavy menstrual bleeding | ETC | Gallagher CS | 2019 | 3,409 | 199,171 | 5.00e-2 | 1.91e-2 |
BMI by age | BMI at 3 years old | ETC | Helgeland O | 2019 | NA | 5,069 | 1.00e-2 | 4.37e-2 |
CCL19 | CCL19 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 4.67e-3 |
CCL19 | CCL19 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 5.24e-4 |
CCL19 | CCL19 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 3.38e-3 |
CCL19 | CCL19 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 7.19e-3 |
IL 6 | Interleukin-6 receptor subunit alpha levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 1.07e-2 |
IL 6 | Interleukin-6 receptor subunit alpha levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 4.01e-2 |
C-X-C chmokine | C-X-C motif chemokine 10 levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 8.80e-4 |
C-X-C chmokine | C-X-C motif chemokine 10 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 3.21e-3 |
C-X-C chmokine | C-X-C motif chemokine 10 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 3.81e-4 |
C-X-C chmokine | C-X-C motif chemokine 10 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 1.92e-2 |
C-X-C chmokine | C-X-C motif chemokine 10 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 3.74e-2 |
CCL24 | CCL24 levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 2.32e-2 |
CCL24 | CCL24 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 5.38e-3 |
CCL24 | CCL24 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 1.17e-2 |
CCL24 | CCL24 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 2.22e-2 |
CCL24 | CCL24 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 1.17e-2 |
CD40 | CD40 ligand levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 2.22e-2 |
CD40 | CD40 ligand levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 1.02e-2 |
CD40 | CD40 ligand levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 3.00e-3 |
CD40 | CD40 ligand levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 1.27e-3 |
CD40 | CD40 ligand levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 5.70e-3 |
CXCL5 | CXCL5 levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 2.79e-2 |
CXCL5 | CXCL5 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 2.03e-2 |
CXCL5 | CXCL5 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 4.05e-2 |
CXCL5 | CXCL5 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 2.68e-2 |
CXCL5 | CXCL5 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 1.81e-2 |
Kallikrein11 | kallikrein-11 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 1.85e-2 |
Kallikrein11 | kallikrein-11 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 8.50e-3 |
Kallikrein11 | kallikrein-11 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 9.20e-3 |
Kallikrein11 | kallikrein-11 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 6.20e-3 |
Epithelial | epithelial cell adhesion molecule levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 3.63e-3 |
Epithelial | epithelial cell adhesion molecule levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 6.10e-3 |
Epithelial | epithelial cell adhesion molecule levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 2.94e-3 |
Epithelial | epithelial cell adhesion molecule levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 9.20e-3 |
Epithelial | epithelial cell adhesion molecule levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 1.81e-2 |
IL 17 | interleukin 17 receptor B levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 4.16e-2 |
IL 17 | interleukin 17 receptor B levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 3.09e-3 |
IL 17 | interleukin 17 receptor B levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 4.45e-2 |
IL 17 | interleukin 17 receptor B levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 2.03e-2 |
IL 17 | interleukin 17 receptor B levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 1.30e-2 |
IL 12 | interleukin 12 receptor subunit beta-1 levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 2.13e-2 |
IL 12 | interleukin 12 receptor subunit beta-1 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 6.15e-3 |
IL 12 | interleukin 12 receptor subunit beta-1 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 2.61e-2 |
IL 12 | interleukin 12 receptor subunit beta-1 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 4.01e-2 |
IL 12 | interleukin 12 receptor subunit beta-1 levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 1.13e-2 |
Endothelial | vascular endothelial growth factor D levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 1.99e-3 |
Endothelial | vascular endothelial growth factor D levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 1.51e-3 |
Endothelial | vascular endothelial growth factor D levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 4.25e-3 |
Endothelial | vascular endothelial growth factor D levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 1.69e-2 |
Endothelial | vascular endothelial growth factor D levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 2.18e-2 |
E-selectin | E-selectin levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 1.23e-2 |
E-selectin | E-selectin levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 2.46e-2 |
E-selectin | E-selectin levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 2.98e-2 |
E-selectin | E-selectin levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 1.13e-2 |
Melanoma | melanoma-derived growth regulatory protein levels | ETC | Enroth S | 2014 | NA | 653 | 5.00e-2 | 1.85e-2 |
Melanoma | melanoma-derived growth regulatory protein levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-2 | 1.20e-3 |
Melanoma | melanoma-derived growth regulatory protein levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-3 | 6.71e-3 |
Melanoma | melanoma-derived growth regulatory protein levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-4 | 1.59e-2 |
Melanoma | melanoma-derived growth regulatory protein levels | ETC | Enroth S | 2014 | NA | 653 | 1.00e-5 | 6.68e-3 |
Glaucoma (MTAG) | Glaucoma (multi-trait analysis) | ETC | Craig JE | 2020 | 119,318 | 232,378 | 1.00e-3 | 4.10e-2 |
Snoring | Snoring main | ETC | Campos AI | 2020 | 152,302 | 256,015 | 1.00e-5 | 1.22e-2 |
Snoring | Snoring adjusted BMI | ETC | Campos AI | 2020 | 151,836 | 255,230 | 1.00e-5 | 4.00e-2 |
Snoring | Snoring male | ETC | Campos AI | 2020 | 90,806 | 99,165 | 1.00e-3 | 1.32e-2 |
Snoring | Snoring male | ETC | Campos AI | 2020 | 90,806 | 99,165 | 1.00e-4 | 1.44e-2 |
Snoring | Snoring Female | ETC | Campos AI | 2020 | 61,792 | 156,554 | 1.00e-5 | 2.63e-2 |
COVID-19 | COVID-19 UKBB EUR tested (Mixed Population) | ETC | GRASP | 2020 | 1,291 | 5,455 | 1.00e-3 | 2.51e-2 |
* If the number of cases is 0/NA, it means the phenotype is a continuous data type and the number of controls is the total number of samples.